OakChart

Spero Therapeutics Inc

SPROHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:05 PM ET

1.02+0.01 (0.99%)
2026-11-11 21:06 CET
Market cap
58.82 USD m
Revenue, TTM
42.96 USD m
Net income, TTM
7.38 USD m
Free cash flow, TTM
19.58 USD m
EPS diluted, TTM
0.11
P/E
9.34
Compare

Price

SPRO against its 20, 50 and 200-day averages
2050200earnings
1.001.502.002.503.005.9M11.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SPROclose 1.0220-day 1.0950-day 1.15200-day 1.931.0252w high

66.9% under the 52-week high of 3.08 on 27 May 2026. 52-week low 0.96 on 5 Nov 2026. Last 15 sessions, 22.8% high to low

Volume 0.24× normal · the line is the 50-bar volume average

Profile

SPRO
52-week range, 3% of the way up
0.963.08

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Employees25
IPONov 02, 2017
Beta1.57
ATR, 14d0.06
Rel volume0.24
Short float1.83%
Insider own26.19%
Inst own18.50%

Snapshot

6 groups

Valuation

Index-
Market Cap59.40M
Enterprise Value10.67M
Income7.38M
Sales42.96M
Book/sh0.76
Cash/sh0.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees25
IPONov 02, 2017

Ratios

P/E9.34
Forward P/E-
PEG-
P/S1.38
P/B1.34
P/C1.17
P/FCF3.03
EV/EBITDA4.14
EV/Sales0.25
Quick Ratio6.12
Current Ratio6.12
Debt/Eq0.05
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)0.11
EPS next Y-0.93
EPS next Q-0.47
EPS this Y-746.67%
EPS next Y4.12%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y7.06% 197.00%
EPS Y/Y TTM114.38%
Sales Y/Y TTM26.04%
EPS Q/Q-443.89%
Sales Q/Q-100.00%
EarningsAug 12 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own26.19%
Insider Trans-0.27%
Inst Own18.50%
Inst Trans4.80%
ROA12.85%
ROE19.17%
ROIC16.69%
Gross Margin-
Oper. Margin6.00%
Profit Margin17.18%
SMA20-6.55%
SMA50-11.03%
SMA200-47.10%
Trades-

Technical

Shs Outstand58.15M
Shs Float42.98M
Short Float1.83%
Short Ratio1.41
Short Interest0.79M
52W High3.08 -66.88%
52W Low0.96 6.14%
Volatility6.61% 5.82%
ATR (14)0.06
RSI (14)41.17
Beta1.57
Rel Volume0.24
Avg Volume558.70K
Volume115,524

Performance

Perf Week-4.67%
Perf Month-11.30%
Perf Quarter-17.74%
Perf Half Y-58.20%
Perf YTD-56.22%
Perf Year-61.07%
Perf 3Y-8.11%
Perf 5Y-93.97%
Perf 10Y-
Recom1.00
Target Price6.00
Prev Close1.01
Price1.02
Change %0.99%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Oct 28, 2026InitiatedCCantor FitzgeraldOverweight$6+488.2%
Dec 20, 2024DowngradeEEvercore ISIOutperform → In-line$5+390.2%
Sep 23, 2022UpgradeEEvercore ISIIn-line → Outperform$2 → $8+684.3%
Oct 01, 2021DowngradeOOppenheimerOutperform → Perform
Jan 22, 2021ReiteratedHH.C. WainwrightBuy$33 → $40+3,821.6%
Dec 16, 2020InitiatedBBerenbergBuy$47+4,507.8%
Sep 29, 2020InitiatedEEvercore ISIOutperform
Nov 05, 2019ReiteratedHH.C. WainwrightBuy$28 → $35+3,331.4%
Sep 09, 2019InitiatedJJanneyBuy
Feb 09, 2018InitiatedCCantor FitzgeraldOverweight$27+2,547.1%

Peers

Mkt cap
TickerCompanyMkt cap
ARMPArmata Pharmaceuticals Inc140.92M
ANTXAN2 Therapeutics Inc169.99M
CRMDCorMedix Inc409.21M
ACXPAcurx Pharmaceuticals Inc5.75M
SCYXScynexis Inc34.29M
MCRBSeres Therapeutics Inc14.27M
VIRVir Biotechnology Inc2.24B
IVVDInvivyd Inc172.49M
ASMBAssembly Biosciences Inc457.08M
BCRXBiocryst Pharmaceuticals Inc1.97B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Rajavelu EstherSee RemarksNov 09 '26Sale1.0440,85142,485946,000Nov 10 06:29 PM
Rajavelu EstherSee RemarksMay 04 '26Sale2.5125,24063,352986,851May 06 09:53 PM
Rajavelu EstherSee RemarksFeb 06 '26Sale2.3687,917207,4841,012,091Feb 09 09:31 PM
Keutzer TimothyChief Operating OfficerFeb 06 '26Sale2.3618,65244,019742,506Feb 09 09:09 PM
Keutzer TimothyChief Operating OfficerFeb 03 '26Sale2.1424,22451,839764,629Feb 05 06:30 AM
Keutzer TimothyChief Operating OfficerFeb 02 '26Sale2.2018,89141,560788,853Feb 05 06:30 AM
Keutzer TimothyChief Operating OfficerFeb 04 '26Sale2.243,4717,775761,158Feb 05 06:30 AM
Rajavelu EstherSee RemarksFeb 02 '26Sale2.2018,44240,5721,100,008Feb 04 09:44 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M

News

latest 14 of 200
  • Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors (GlobeNewswire) -5.61%
  • Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Spero Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
  • Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline (GlobeNewswire)
  • Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference (GlobeNewswire)
  • Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
  • Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... (GuruFocus.com)
  • Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update (GlobeNewswire)
  • Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 (GlobeNewswire) +6.96%
  • Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
  • Innovent licenses IBI355 rights to Spero for up to $1.1bn (Pharmaceutical Technology)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.160--0.1600.00--
2026Q12026-05-13-0.130--0.1260.26--
2025Q42026-03-260.530-0.53141.30--
2025Q32025-11-13-0.130-0.250-0.1315.44-1
2025Q22025-08-12-0.030-0.380-0.03014.19-1
2025Q12025-05-13-0.250-0.550-0.2505.8711.001
2024Q42025-03-27-0.380-0.310-0.38315.0412.402
2024Q32024-11-14-0.320-0.265-0.31713.4723.002
2024Q22024-08-05-0.330-0.380-0.33110.204.903
2024Q12024-05-15-0.240-0.043-0.2379.2721.533
2023Q42024-03-130.960-0.1000.96473.5218.633
2023Q32023-11-13-0.060-0.030-0.06125.4714.973
2023Q22023-08-10-0.230-0.343-0.2272.701.083
2023Q12023-05-11-0.250-0.333-0.2532.071.273
2022Q42023-03-300.550-0.3530.55047.440.873
2022Q32022-11-14-0.330-0.303-0.3252.015.423

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.350-3.104-3.35518.1518.22
2020FY-3.520-3.467-3.5219.3311.07
2021FY-2.910-2.725-2.90518.2619.96
2022FY-1.230-1.970-1.23553.517.12
2023FY0.430-0.6450.430103.7848.90
2024FY-1.270-0.920-1.26947.9838.97
2025FY0.150-0.1000.15066.80-
2026FY--0.970--0.28
2027FY--0.930--0.00
2028FY--1.040--0.00
2029FY--1.110--6.30
2030FY--1.190--8.80

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-272000.000.000.00
2026Q3S2026-09-111000.000.000.00
2026Q3E2026-10-27200-0.47-0.80-0.14
2026Q3E2026-09-11100-0.14-0.14-0.14
2026Q3E2025-11-14110-0.16-0.16-0.16
2026Q3E2025-11-11100-0.18-0.18-0.18
2026Q3E2025-11-10100-0.18-0.18-0.18
2026Q3E2025-11-09100-0.18-0.18-0.18
2026Q3E2025-11-08100-0.18-0.18-0.18
2026Q3E2025-11-07100-0.18-0.18-0.18
2026Q3E2025-11-06100-0.18-0.18-0.18
2026Q3E2025-11-05100-0.18-0.18-0.18
2026Q3E2025-11-04100-0.18-0.18-0.18
2026Q3E2025-11-03100-0.18-0.18-0.18

Estimate history

EPS, annual-17.82-2.604-3.355-3.521-2.905-1.2350.43-1.2690.1450.1092
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.331-0.317-0.383-0.25-0.03-0.1310.531-0.126-0.165
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.9793.96618.1470.2583.0748.57996.73527.39659.61942.96
Period201720182019202020212022202320242025TTM
Sales, quarterly6.0177.8199.3565.11111.8023.04839.6580.2580
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual14.36917.20619.19129.2632.39452.4565354.59456.41558.147
Period201720182019202020212022202320242025MRQ
Shares, quarterly54.00954.31454.59455.90156.18756.31256.41557.89158.147
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue42.9659.6227.4096.7348.583.070.2618.153.97
Cost of Goods Sold Incl. D&A--0.000.371.551.12---
Gross Profit--27.3996.3747.031.95---
Selling, General and Administrative Excl. Other40.3859.64120.4676.6382.53105.1187.1080.2046.36
Research and Development20.5338.4796.7551.0746.0563.4166.2464.6233.88
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income2.58-0.02-93.0619.74-35.50-103.16-88.19-63.22-42.81
Interest Expense0.000.000.000.002.601.940.000.000.00
Unusual Expense0.590.840.885.3114.29-0.200.00-0.220.00
Net Income Before Taxes7.648.83-68.5725.40-46.41-89.76-78.28-60.92-41.66
Income Taxes0.260.260.002.600.000.000.000.000.00
Consolidated Net Income7.388.57-68.5722.81-46.41-89.76-78.28-60.92-41.66
Net Income From Continuing Operations7.388.57-68.5722.81-46.41-89.76-78.28-60.92-41.66
Net Income7.388.57-68.5722.81-46.41-89.76-78.83-60.92-41.66
EPS (Recurring)0.130.16-1.260.50-0.97-2.91-3.52-3.36-2.60
EPS (Basic, Before Extraordinaries)0.140.15-1.270.43-1.23-2.91-3.52-3.35-2.60
EPS (Diluted)0.110.15-1.270.43-1.23-2.91-3.52-3.35-2.60
EBITDA2.58-0.02-93.0620.11-33.95-102.04-86.84-62.06-42.40
Non-Operating Income (Expense)5.659.7025.3810.975.9815.149.902.071.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.783.427.796.279.129.434.893.782.75
Price To Earnings Ratio9.259.2512.97153.12-----
Price To Sales Ratio2.982.312.030.811.34161.121,682.439.6224.81
Gross Margin--99.9999.6296.8263.62---
Operating Margin6.00-0.04-339.7020.41-73.07-3,360.16-34,180.23-348.36-1,079.32
Net Margin17.1814.38-250.2823.58-95.55-2,923.65-30,553.88-335.73-1,050.48
Shares Outstanding58.1556.4154.5953.0052.4632.3929.2619.1917.21
Market Capitalization58.8258.8256.1577.9189.57517.50527.35183.92105.82

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.2639.663.0511.805.119.367.82
Cost of Goods Sold Incl. D&A0.00-------
Gross Profit0.00-------
Selling, General and Administrative Excl. Other9.937.809.8912.7716.5520.4335.8932.06
Research and Development3.432.915.598.6010.6713.6128.8426.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.93-7.5429.77-9.72-4.75-15.32-26.54-24.24
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.590.080.170.880.00
Net Income Before Taxes-9.55-7.2031.78-7.38-1.70-13.87-20.60-17.44
Income Taxes0.000.000.260.000.000.000.29-0.29
Consolidated Net Income-9.55-7.2031.52-7.38-1.70-13.87-20.89-17.15
Net Income From Continuing Operations-9.55-7.2031.52-7.38-1.70-13.87-20.89-17.15
Net Income-9.55-7.2031.52-7.38-1.70-13.87-20.89-17.15
EPS (Recurring)-0.16-0.130.53-0.12-0.03-0.25-0.37-0.32
EPS (Basic, Before Extraordinaries)-0.16-0.130.56-0.13-0.03-0.25-0.38-0.32
EPS (Diluted)-0.16-0.130.53-0.13-0.03-0.25-0.38-0.32
EBITDA-9.93-7.5429.77-9.72-4.75-15.32-26.54-24.24
Non-Operating Income (Expense)0.370.342.022.933.131.636.826.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.821.110.801.050.711.561.191.70
Price To Earnings Ratio9.2519.66----12.974.00
Price To Sales Ratio2.982.452.323.614.771.412.050.81
Operating Margin--2,921.7175.06-319.00-40.23-299.73-283.63-310.05
Net Margin--2,791.8679.48-242.19-14.40-271.30-223.26-219.30
Shares Outstanding58.1557.8956.4156.3156.1955.9054.5954.31
Market Capitalization58.82135.47131.27105.80162.1439.2556.1572.43

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments40.2752.8976.33109.11146.40126.9182.05115.4487.29
Short Term Receivables25.3952.4850.701.082.646.1810.251.302.94
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.631.914.183.388.836.063.127.481.83
Total Current Assets67.29107.28131.21113.57157.87139.1595.41124.2292.06
Net Property, Plant & Equipment1.483.114.165.497.568.787.152.891.16
Total Investments and Advances0.000.000.000.000.000.000.000.000.05
Long-Term Note Receivable-0.0046.59---0.020.230.00
Intangible Assets-------0.000.00
Other Assets0.150.150.435.745.645.523.521.660.21
Total Assets68.92110.54182.39124.80171.07153.45106.10129.0193.48
Short Term Debt Incl. Current Port. of LT Debt1.961.751.721.691.360.950.930.000.00
Accounts Payable0.697.311.380.621.101.164.153.603.47
Income Tax Payable0.380.170.39------
Other Current Liabilities5.8439.8533.6719.3416.2112.2421.598.714.69
Total Current Liabilities8.8749.0737.1521.6518.6714.3426.6612.328.16
Long Term Debt0.942.553.834.9654.396.894.620.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.0912.7934.5222.269.730.180.250.830.36
Total Liabilities9.9064.4275.5048.8782.7821.4131.5313.158.52
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity59.0246.12106.8975.9388.29132.0474.57115.5084.60
Total Shareholders Equity59.0246.12106.8975.9388.29132.0474.57115.5084.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.350.35
Total Equity59.0246.12106.8975.9388.29132.0474.57115.8684.96
Total Liabilities & Stockholders Equity68.92110.54182.39124.80171.07153.45106.10129.0193.48
Book Value Per Share1.050.842.021.452.734.513.896.715.89
Tangible Book Value Per Share1.050.842.021.452.734.513.896.715.89
Full-Time Employees2532463514689574135
Price to Book Ratio1.330.851.452.285.874.302.470.92-0.05
Return on Assets9.55-46.8114.85-31.37-55.32-60.32-51.83-37.45-72.25
Return on Equity16.31-89.6224.95-56.53-81.47-75.77-64.11-41.64-81.76
Return on Invested Capital14.30-140.8720.60-57.38-62.91-56.34-76.93-36.07-45.79
Quick Ratio7.592.193.535.258.469.703.5810.0811.29
Current Ratio7.592.193.535.258.469.703.5810.0811.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income7.388.57-68.5722.81-46.41-89.76-78.28-60.92-41.66
Depreciation-0.000.000.371.551.121.351.160.41
Other Funds (Non Cash)5.535.968.8414.2115.0511.434.532.972.70
Funds from Operations12.9114.53-59.7337.38-29.82-77.21-72.41-56.80-38.55
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital6.67-27.1636.28-70.3822.0912.86-13.466.78-1.07
Income Taxes Payable0.000.21-0.210.39-----
Cash from Operating Activities19.58-12.62-23.44-32.99-7.73-64.35-85.87-50.02-39.62
Capital Expenditures0.000.000.000.000.000.00-0.16-0.31-2.44
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.040.000.000.00
Purchase or Sale of Investments0.000.000.000.0033.817.6310.6329.84-80.72
Purchase of Investments0.000.000.000.00-26.97-43.91-45.72-88.99-130.18
Sale Or Maturity of Investments0.000.000.000.0060.7851.5556.35118.8449.45
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.0033.817.6710.4729.53-83.16
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.2224.9336.57130.8816.1469.52
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.2224.9336.57130.8816.1469.52
Proceedsfrom Stock Options0.000.000.000.2224.5135.12128.6915.6369.19
Issuance or Reduction of Debt, Net0.000.000.000.00-54.4847.480.000.000.00
Change in Long Term Debt0.000.000.000.00-54.4847.480.000.000.00
Issuance of Long Term Debt0.000.000.000.000.0049.750.000.000.00
Reduction of Long Term Debt0.000.000.000.00-54.48-2.270.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.22-29.5584.05130.8816.1469.52
Net Change in Cash19.58-12.62-23.44-32.77-3.4827.3855.48-4.35-53.26
Free Cash Flow19.58-12.62-23.44-32.99-7.73--86.03-50.33-42.06
Preferred Dividends (Cash Flow)-0.000.000.000.00--0.000.00
Price to Free Cash Flow6.54--------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments50.7756.1340.2748.6231.1948.89
Short Term Receivables0.030.0425.392.4626.9124.28
Inventories0.000.000.000.000.000.00
Other Current Assets0.791.441.631.251.291.55
Total Current Assets51.5857.6167.2952.3259.4074.71
Net Property, Plant & Equipment1.031.261.481.692.562.84
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets---0.00--
Other Assets0.150.150.150.150.150.15
Total Assets52.7759.0268.9254.1762.1277.71
Short Term Debt Incl. Current Port. of LT Debt2.001.971.961.901.841.79
Accounts Payable0.150.220.691.400.781.76
Income Tax Payable0.160.160.380.160.160.17
Other Current Liabilities6.113.145.8410.1912.1625.42
Total Current Liabilities8.435.498.8713.6514.9529.16
Long Term Debt0.040.510.941.451.772.17
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.090.090.0912.5712.5712.57
Total Liabilities8.566.099.9027.6829.2943.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity44.2052.9359.0226.4932.8333.81
Total Shareholders Equity44.2052.9359.0226.4932.8333.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity44.2052.9359.0226.4932.8333.81
Total Liabilities & Stockholders Equity52.7759.0268.9254.1762.1277.71
Book Value Per Share0.760.911.050.470.580.60
Tangible Book Value Per Share0.760.911.050.470.580.60
Full-Time Employees--25---
Price to Book Ratio1.332.244.953.224.790.85
Return on Assets12.8522.289.55-46.31-50.57-56.85
Return on Equity19.1735.1216.31-95.29-94.59-107.28
Return on Invested Capital-21.59-13.4852.57-26.42-4.91-38.54
Quick Ratio6.1210.507.593.833.972.56
Current Ratio6.1210.507.593.833.972.56

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.55-7.2031.52-7.38-1.70-13.87
Depreciation--0.000.00--
Other Funds (Non Cash)1.051.341.221.920.991.83
Funds from Operations-8.50-5.8632.74-5.46-0.71-12.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.1521.73-41.0922.89-16.988.04
Income Taxes Payable0.00-0.220.220.00--
Cash from Operating Activities-5.3615.86-8.3517.42-17.69-4.00
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.000.000.00
Net Change in Cash-5.3615.86-8.3517.42-17.69-4.00
Free Cash Flow-5.3615.86-8.3517.42-17.69-4.00
Price to Free Cash Flow6.5418.51----

Revenue breakdown

Collaboration2024: 371.00K 2025: 12.59M
Collaboration Revenue Related Party2024: 27.03M 2025: 47.03M
Grant2024: 20.58M 2025: 7.18M
United States2024: 47.98M 2025: 66.80M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.83%0.8M43.0M604.61K
2026-10-151.96%0.8M43.0M1.00M
2026-09-301.85%0.8M43.0M1.18M
2026-09-152.27%1.0M43.0M1.44M
2026-08-312.82%1.2M43.0M1.51M
2026-08-143.37%1.4M42.9M1.60M
2026-07-313.54%1.5M42.8M1.58M
2026-07-154.94%2.1M42.8M1.18M
2026-06-306.69%2.9M42.8M985.57K
2026-06-154.27%1.8M42.9M588.06K
2026-05-293.98%1.7M42.9M503.30K
2026-05-153.84%1.6M42.9M423.40K
2026-04-302.75%1.2M42.9M387.14K
2026-04-151.74%0.7M42.3M361.86K
2026-03-311.45%0.6M41.9M312.67K
2026-03-131.32%0.5M40.8M296.16K
2026-02-271.41%0.6M40.8M293.25K
2026-02-131.76%0.7M40.8M304.15K
2026-01-302.32%0.9M40.7M333.50K
2026-01-152.54%1.0M40.9M579.02K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.101.100.0032.9940.000.000.905-0.0070.000
call1.000.000.350.185.55940.000.000.629-0.0130.001
call1.500.000.200.055.0492.000.000.475-0.0170.001
call2.000.000.050.003.6020.000.000.195-0.0080.000
call2.500.001.000.004.4640.000.000.174-0.0100.000
call5.000.004.900.006.3560.000.000.140-0.0130.000
call7.500.004.900.007.3660.000.000.129-0.0140.000
put0.500.000.050.044.6601.000.00-0.096-0.0070.000
put1.000.000.150.102.38361.000.00-0.362-0.0130.001
put1.500.051.050.4011.5664.000.00-0.525-0.0190.001
put2.000.501.500.0011.7110.000.00-0.805-0.0090.000
put2.501.002.000.0012.4620.000.00-0.826-0.0100.000
put5.001.506.500.000.0000.000.00-0.860-0.0120.000
put7.504.008.900.000.0000.000.00-0.871-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-10SEC
2026-11-103Initial statement of beneficial ownership of securities2026-11-10SEC
2026-11-108-KCurrent report2026-11-09SEC
2026-10-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-278-KCurrent report2026-10-26SEC
2026-09-10EFFECTEffectiveness filing by commission orderSEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-28S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-03SEC
2026-07-148-KCurrent report2026-07-08SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-258-KCurrent report2026-06-23SEC
2026-06-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-228-KCurrent report2026-06-17SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110042.49K1
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050063.35K1
2026-040000
2026-030000
2026-0200393.25K6
2026-010000
2025-120000
2025-110095.44K1

Institutional holders

Manager% owned
GSK plc15.78%
PFIZER INC4.08%
VANGUARD CAPITAL MANAGEMENT LLC3.52%
MACKENZIE FINANCIAL CORP3.14%
RENAISSANCE TECHNOLOGIES LLC1.64%
Alphabet Inc.1.54%
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.31%
BlackRock, Inc.1.03%
RAYMOND JAMES FINANCIAL INC0.90%
GEODE CAPITAL MANAGEMENT, LLC0.86%

Funds

Fund% owned
Bond Fund18.18%
Investment Grade Bond Fund4.30%
MEDIUM-DURATION BOND FUND2.58%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.41%
John Hancock Core Bond ETF2.22%
Short Duration Bond Fund1.98%
John Hancock Managed Account Shares Securitized Debt Portfolio1.54%
Balanced Fund1.25%
VANGUARD EXTENDED MARKET INDEX FUND1.02%
Morningstar Total Return Bond Fund0.94%

OakChart. SPRO. Cached 15 minutes.